Eli Lilly (LLY) announces that from January 1st 2027, Zepbound, Mounjaro and Orforglipron will be available through Medicare Part D participating plans

Eli Lilly's announcement regarding Medicare Part D coverage for its key products suggests a significant market expansion for Zepbound, Mounjaro, and Orforglipron, improving affordability for patients.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

The White House is mulling releasing oil from the Strategic Petroleum Reserve but so far has not made a formal decision, Politico sources say; "But there is pretty fierce opposition to tapping SPR — it’s a half measure at best"

Official Source of the Ministry of Energy says the pumping of gas to Egypt has been completely halted since the beginning of the war; Any talk of a return to pumping at small rates is completely incorrect, via Attaqa News

Eli Lilly (LLY) announces that from January 1st 2027, Zepbound, Mounjaro and Orforglipron will be available through Medicare Part D participating plans

US Secretary of State Rubio says goals are clear, to destroy missiles; Iran is a terroristic regime and attacking its neighbors; is trying to destroy Iran's navy

Iraq's Kirkuk crude flows to the Ceyhan port of Turkey stopped on the 9th of March, according to sources

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • On cmmi balance model for GLP-1s, patient's cost-sharing will be limited to USD 245/month plus dispensing fee before patients reach their deductible
Context

This move could enhance Eli Lilly's revenue growth prospects and boost sentiment toward pharmaceutical stocks, as it reflects strategic positioning in a competitive sector. Investors should monitor potential impacts on overall healthcare expenditure and competitors' responses in the market.

Related headlines

The whole workspace, free to try.

Try it free